Antibody/Fusion Protein Core

我们已经成功地创造并鉴定了一组单抗和免疫球蛋白 相关融合蛋白。各种不同的技术，包括cdna免疫已经成功。 在Kuchroo博士的实验室中用于制造针对可溶性和细胞表面蛋白的单抗。我们 已经制造了针对小鼠、人类、大鼠和仓鼠蛋白的抗体。此外，郑博士还成功地 产生了数十种免疫球蛋白融合蛋白。为了了解一种新发现的蛋白质Ig的生物学功能 融合蛋白已被用于鉴定分子的体外和体内功能。在这一努力中 细胞因子或细胞表面蛋白已经与免疫球蛋白重链融合，最近我们发现 在新小郑、维贾伊·库奇鲁和特里·B·斯特罗姆之间建立了合作核心，建立了 以色列贝丝女执事医疗中心移植研究中心内的抗体和融合蛋白核心 布里格姆妇女医院神经科疾病中心。这两个中心都位于 哈佛医学院。调查人员定期会面，按计划举行临时会议 咨询。研究人员有很长一段合作和生产单抗的历史 抗体和融合蛋白针对多个细胞表面靶点。最近的合作导致了 新型TIM家族分子的单抗和Ig融合蛋白的制备 发现了表达在T细胞表面的免疫调节分子。抗病毒抗体 可以产生特定的蛋白质，作为激动剂并激活受体或拮抗剂 并阻断分子的功能。另一方面，免疫球蛋白融合蛋白具有以下优势 与天然配体结合，可用作鉴定和分子克隆配体的工具。 此外，Ig融合蛋白可以作为阻断剂干扰受体：配体的结合。 相互作用，因此有助于了解分子的体内功能。免疫球蛋白还 具有较长的半衰期和最低的免疫原性，因此可以在体内成功地用于 了解新发现的分子的功能。抗体和Ig融合蛋白是 独特的试剂，已被证明是促进许多创新研究的强大工具 FIELS和一些已被证明是治疗人类自身免疫的有效免疫调节试剂 疾病、癌症和诱导移植耐受。 抗体和融合蛋白核心的目标将是提供一个平台，用于开发单克隆和 新发现的分子或基因的多克隆抗体和新型治疗性免疫球蛋白融合蛋白 PPG。我们的角色将是为新鉴定的蛋白质提供抗体和融合蛋白。而当 核心产生的蛋白质不会在GMP设施中制造，GMP设施是用于生产的细胞系 将达到FDA的标准。因此，未来将有可能轻松地进行临床试验。

We have been successful in our effort to create and characterize a panel of monoclonal antibodies and Ig related fusion proteins. Various different techniques, including cDNA immunization have been successfully used in Dr. Kuchroo' laboratory to make monoclonal antibodies to soluble and cell surface proteins. We have made antibodies to mouse, human, rat and hamster proteins. In addition, Dr. Zheng has successfully generated dozens of Ig-fusion proteins. To understand biological functions of a newly identified protein, Ig fusion proteins have been utilized for identifying in vitro and in vivo function of the molecules. In this effort cytokines or cell surface proteins have been fused with the heavy chain of IgG, and we have recently established a collaborative core between Xin Xiao Zheng, Vijay Kuchroo and Terry B. Strom to build a antibody and fusion protein Core within the Transplant Research Center at Beth Israel Deaconess Medical Center and Center for Neurologic Diseases, Brigham and Women's Hospital. Both Centers are located in the Harvard Institutes of Medicine. The investigators meet regularly for planned meeting for impromptu consultation. The investigators have a long history of working together and producing monoclonal antibodies and fusion proteins to a number of cell surface targets. The recent collaboration has led to the generation of monoclonal antibodies and Ig fusion proteins to TIM family of molecules, a family of newly discovered immunoregulatory molecules expressed on the surface of T cells. The antibodies against specific proteins can be generated that can act as an agonist and activate the receptor or an antagonist and block the function of the molecule. Ig fusion proteins, on the other hand, have an advantage of binding to the natural ligand and can be utilized as tools to identify and molecularly clone the ligand. Furthermore, Ig fusion proteins can act as blocking agents and interfere with the binding of receptor:ligand interaction and therefore help in the understanding the in vivo function of the molecule. Ig proteins also have long half-lives and minimal immunogenicity, therefore can be used successfully in vivo for understanding the function of the newly identified molecule. The antibodies and Ig fusion proteins are unique reagents and have been proven to be a powerful tools to facilitate innovative research in many fields and some have proven to be potent immunomodulatory reagents to treat human autoimmune diseases, cancer and induce transplantation tolerance. The goals of antibody and fusion protein Core will be to provide a platform for developing monoclonal and polyclonal antibodies and novel therapeutic Ig.fusion proteins for newly discovered molecules or genes for PPG. Our role will be to provide antibodies and fusion proteins for newly identified proteins. While the proteins produced by the core will not be manufactured in a GMP facility, the cell lines used for production will meet FDA standards. Thus it will be possible to easily progress to a clinical trial in the future.